Kottke TJ - Search Results

1

Antibody-Neutralized Reovirus Is Effective in Oncolytic Virotherapy.

Berkeley RA, Steele LP, Mulder AA, van den Wollenberg DJM, Kottke TJ, Thompson J, Coffey M, Hoeben RC, Vile RG, Melcher A, Ilett EJ. Berkeley RA, et al. Among authors: kottke tj. Cancer Immunol Res. 2018 Oct;6(10):1161-1173. doi: 10.1158/2326-6066.CIR-18-0309. Epub 2018 Sep 12. Cancer Immunol Res. 2018. PMID: 30209061 Free article.

2

Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells.

Bateman AR, Harrington KJ, Kottke T, Ahmed A, Melcher AA, Gough MJ, Linardakis E, Riddle D, Dietz A, Lohse CM, Strome S, Peterson T, Simari R, Vile RG. Bateman AR, et al. Cancer Res. 2002 Nov 15;62(22):6566-78. Cancer Res. 2002. PMID: 12438252

3

Pharmacologically regulated production of targeted retrovirus from T cells for systemic antitumor gene therapy.

Crittenden M, Gough M, Chester J, Kottke T, Thompson J, Ruchatz A, Clackson T, Cosset FL, Chong H, Diaz RM, Harrington K, Alvarez Vallina L, Vile R. Crittenden M, et al. Cancer Res. 2003 Jun 15;63(12):3173-80. Cancer Res. 2003. PMID: 12810645

4

Intratumoral expression of a fusogenic membrane glycoprotein enhances the efficacy of replicating adenovirus therapy.

Ahmed A, Jevremovic D, Suzuki K, Kottke T, Thompson J, Emery S, Harrington K, Bateman A, Vile R. Ahmed A, et al. Gene Ther. 2003 Sep;10(19):1663-71. doi: 10.1038/sj.gt.3302064. Gene Ther. 2003. PMID: 12923565

5

A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccines.

Phan V, Errington F, Cheong SC, Kottke T, Gough M, Altmann S, Brandenburger A, Emery S, Strome S, Bateman A, Bonnotte B, Melcher A, Vile R. Phan V, et al. Nat Med. 2003 Sep;9(9):1215-9. doi: 10.1038/nm923. Epub 2003 Aug 17. Nat Med. 2003. PMID: 12925849

6

A simple method to cure established tumors by inflammatory killing of normal cells.

Daniels GA, Sanchez-Perez L, Diaz RM, Kottke T, Thompson J, Lai M, Gough M, Karim M, Bushell A, Chong H, Melcher A, Harrington K, Vile RG. Daniels GA, et al. Nat Biotechnol. 2004 Sep;22(9):1125-32. doi: 10.1038/nbt1007. Epub 2004 Aug 1. Nat Biotechnol. 2004. PMID: 15300260 Free article.

7

Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo.

Sanchez-Perez L, Kottke T, Diaz RM, Ahmed A, Thompson J, Chong H, Melcher A, Holmen S, Daniels G, Vile RG. Sanchez-Perez L, et al. Cancer Res. 2005 Mar 1;65(5):2009-17. doi: 10.1158/0008-5472.CAN-04-3216. Cancer Res. 2005. PMID: 15753401

8

Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells.

Cole C, Qiao J, Kottke T, Diaz RM, Ahmed A, Sanchez-Perez L, Brunn G, Thompson J, Chester J, Vile RG. Cole C, et al. Nat Med. 2005 Oct;11(10):1073-81. doi: 10.1038/nm1297. Epub 2005 Sep 18. Nat Med. 2005. PMID: 16170322

9

Allogeneic tumor cells expressing fusogenic membrane glycoproteins as a platform for clinical cancer immunotherapy.

Errington F, Bateman A, Kottke T, Thompson J, Harrington K, Merrick A, Hatfield P, Selby P, Vile R, Melcher A. Errington F, et al. Clin Cancer Res. 2006 Feb 15;12(4):1333-41. doi: 10.1158/1078-0432.CCR-05-1113. Clin Cancer Res. 2006. PMID: 16489091 Free article.

10

The perforin-dependent immunological synapse allows T-cell activation-dependent tumor targeting by MLV vector particles.

Kottke T, Qiao J, Diaz RM, Ahmed A, Vroman B, Thompson J, Sanchez-Perez L, Vile R. Kottke T, et al. Gene Ther. 2006 Aug;13(15):1166-77. doi: 10.1038/sj.gt.3302722. Epub 2006 Apr 20. Gene Ther. 2006. PMID: 16625245

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

97 results

Search Page